Dehydroabietic Acid

Dehydroabietic Acid

SCHEMBL19798161

CC(C)c1ccc2c(c1)CC[C@H]1[C@](C)(C(=O)O)CCC[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KARS1 Q15046 5/20 1.00
▸ RXRA P19793 1/20 1.00
▸ CCNE1 P24864 1/20 1.00
▸ CDK2 P24941 1/20 1.00
▸ RXRB P28702 1/20 1.00
▸ RXRG P48443 1/20 1.00
▸ CYP3A4 P08684 4/20 0.81
▸ LMNA P02545 1/20 0.81
▸ POLB P06746 1/20 0.67
▸ APEX1 P27695 1/20 0.67
▸ PDE4D Q08499 1/20 0.67
▸ MEN1 O00255 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ CYP2D6 P10635 2/20 0.64
▸ CYP2C19 P33261 2/20 0.64
▸ TSHR P16473 2/20 0.64
▸ PDK1 Q15118 1/20 0.64
▸ PDK2 Q15119 1/20 0.64
▸ PDK3 Q15120 1/20 0.64
▸ PDK4 Q16654 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dehydroabietic Acid SCHEMBL222078 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL15313390 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL14653170 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL222079 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL18019015 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL2603437 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL15744753 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL20061641 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL678991 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB
Dehydroabietic Acid SCHEMBL9712221 1.00 KARS1 (1.00) KARS1RXRACCNE1CDK2RXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180021303-A1 BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER CANBEX THERAPEUTICS LTD (GB) 2018-01-25 — — US disclosed
US-20180021303-A1 BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER CANBEX THERAPEUTICS LTD (GB) 2018-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021303-A1 BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER KCNMA1, KCNMB1, KCNA1 KARS1 440/4885RXRA 2511/4885CCNE1 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback